Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Cash from Financing Activities data on file, last reported at $6.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $18.6 million, up 3.82% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $6.1 million, up from $4.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for VVOS reached as high as $7.4 million in Q2 2024 and fell as low as $2.8 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $4.7 million across 4 years, with a median of $3.8 million in 2024.
• Across the five-year window, Cash from Financing Activities plunged 50.58% in 2024 and surged 41.94% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $3.6 million in 2023, then declined by 14.41% to $3.1 million in 2024, then soared by 41.94% to $4.3 million in 2025, then surged by 40.92% to $6.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $6.1 million in Q1 2026, $4.3 million in Q4 2025, and $2.8 million in Q3 2025.